Assertio Therapeutics

Assertio Therapeutics products

Cambia (diclofenac potassium oral solution)
Indication: Treatment of acute migraine-associated pain, nausea, photophobia, and phonophobia.

INDOCIN (indomethacin oral solution & suppositories)
Indication: Management of moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis flares, acute shoulder pain, and gouty arthritis.

Otrexup (methotrexate subcutaneous auto-injector)
Indication: Treatment of severe, active rheumatoid arthritis; active polyarticular juvenile idiopathic arthritis; and severe, recalcitrant psoriasis.

Rolvedon (eflapegrastim-xnst injection)
Indication: Reduction of febrile neutropenia risk via long-acting G-CSF support—it joined Assertio’s portfolio through the Spectrum Pharmaceuticals acquisition.

Sprix (ketorolac tromethamine nasal spray)
Indication: Short-term management of moderate to moderately severe pain requiring analgesia at the opioid level.

Sympazan (clobazam oral film)
Indication: Adjunctive treatment for seizures associated with Lennox–Gastaut syndrome in patients two years of age and older.

Zipsor (diclofenac potassium liquid-filled capsules)
Indication: Relief of mild to moderate acute pain.